NCT04979390Unknown1 期
A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of New Formulation SHR-1316 in Subjects With Advanced Tumors
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 15
- 主要终点
- Elimination half-life (t1/2)
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of the new formulation SHR-1316 in subjects with advanced tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years.
- •Histologically or cytologically confirmed advanced cancer in patients who are fail to current standard therapy or lack of effective therapy.
- •Estimated life expectancy ≥12 weeks.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Adequate organ functions.
- •If of childbearing potential (male or female), agrees to practice an effective form of contraception during study treatment and for at least 3 months following last treatment dose.
- •Patients must be willing and able to provide written informed consent prior to the performance of any study-specific procedure.
排除标准
- •Known history of hypersensitivity to any components of the SHR-1316 product.
- •Patient- Prior treatment with the following agents:
- •"Check-point inhibitors", including Programmed death receptor-1 (PD-1), PD-L1;
- •Receipt of investigational agents within 4 weeks prior to study treatment;
- •Current treatment on another therapeutic clinical trial, unless the observational (non-interventional) clinical trials or follow-up of interventional clinical trials;
- •Any anti-cancer therapy (including chemotherapy, immunotherapy, hormone therapy, target therapy, biotherapy or tumor embolization), administered within 4 weeks prior to study treatment; or within 6 weeks in the case of certain therapies (e.g., mitomycin C and nitrosoureas). Any such, unless discussed and explained with the sponsor;
- •Anticipated need for any anti-cancer therapy (including chemotherapy, immunotherapy, hormone therapy, or biotherapy) during SHR-1316 treatment; except palliative radiotherapy;
- •Receipt of any anti-cancer vaccines; receipt of immunomodulatory drugs within 4 weeks prior to study treatment; topical, nasal spray and inhaled corticosteroids as well as systemic steroid therapy in physiological doses (such as: prednisone ≤10 mg/day) are acceptable.
- •Patients have unrecovered (ie, to NCI CTCAE grade ≤1) from all toxicity associated with previous treatments (exception: patients may enter with continuing alopecia irrespective of CTCAE grade; grade 2 peripheral nerve diseases).
- •Known Active central nervous system (CNS) metastases; Patients who had previously received brain or meningeal metastasis therapy, who were clinically stable for at least 8 weeks, and who had stopped systemic sex hormone therapy (such as： prednisone > 10 mg/day) for more than 4 weeks were included.
- •Subjects with active autoimmune disease, history of autoimmune diseases, including but not limited to myasthenia gravis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, etc.
- •Active or history of immune deficiency, such as human immunodeficiency virus (HIV) infection; History of organ transplantation.
- •History or evidence of cardiovascular (CV) risk including any of the following: Congestive heart failure (Class >2) as defined by the New York Heart Association functional classification system (NYHA), unstable angina pectoris, Recent (within the past 12 months) history of myocardial infarction, clinically significant supraventricular or ventricular arrhythmias need treatment or intervention.
- •Patients with clinically significant ECG abnormalities (QT interval corrected for rate by Fridericia's formula [QTcF] >470 msec for female and >450 msec for male on the ECG obtained at Screening).
- •Active infection that need drug intervention or an unexplained fever >38.5°C (fever caused by cancer can be included according to the judgement of the researcher).
- •Active pulmonary tuberculosis infection.
- •Positive for Hepatitis B or C.
- •Known history of psychoactive drug abuse, alcohol abuse or drug use.
- •Known history of any other malignant cancer within past 3 years. Exceptions: completely resected basal cell carcinoma and squamous cell carcinoma of the skin; and completely resected carcinoma in situ of cervix.
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study.
研究组 & 干预措施
Treatment group
Experimental
干预措施: SHR-1316 (Drug)
结局指标
主要结局
Elimination half-life (t1/2)
时间窗: approximately 1 year
Clearance (CL)
时间窗: approximately 1 year
Trough concentration (Cmin)
时间窗: approximately 1 year
The incidence and severity of adverse events/serious adverse events (based on NCI-CTC AE 5.0)
时间窗: approximately 1 year
Maximum plasma concentration (Cmax)
时间窗: approximately 1 year
Time to maximum concentration (Tmax)
时间窗: approximately 1 year
Accumulatio of ratio (Rac)
时间窗: approximately 1 year
Area under the concentration-time curve from time zero to time（AUC0-t）
时间窗: approximately 1 year
Area under the concentration-time curve extrapolated to infinity (AUC0-∞.)
时间窗: approximately 1 year
Volume of distribution (Vz)
时间窗: approximately 1 year
次要结局
- Immunogenicity of SHR-1316(approximately 1 year)
- Progression-free survival (PFS)(approximately 1 year)
- Objective response rate (ORR)(approximately 1 year)
- Duration of response (DoR)(approximately 1 year)
- Disease control rate (DCR)(approximately 1 year)
- Overall survival (OS)(approximately 1 year)
研究者
相似试验
招募中
1 期
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.AnemiaNCT05773586Ascentage Pharma Group Inc.105
终止
1 期
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsAdvanced Solid TumorsMSI-H/dMMR TumorsCutaneous Squamous Cell CarcinomaUrothelial Carcinoma, HCCEsophageal Squamous Cell CarcinomaSmall-cell Lung CancerCervical CancerMerkel Cell CarcinomaMesotheliomaPD-L1 Amplified Tumor (9p24.1)Cyclin-dependent Kinase 12 Mutated TumorsBasal Cell Carcinoma (Unresectable or Metastatic)Sarcomatoid Renal Cell CarcinomaClear Cell Ovarian or Endometrial CarcinomaAnal CarcinomaSquamous Cell Penile CarcinomaNasopharyngeal CarcinomaDNA Polymerase Epsilon Mutated Tumors (P286R and V411L)NCT04272034Incyte Corporation105
进行中（未招募）
1 期
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic MalignanciesNon Hodgkin LymphomaChronic Lymphocytic LeukemiaNCT03913949Ascentage Pharma Group Inc.74
撤回
1 期
3D011-08 Monotherapy in Subjects With Advanced Solid TumorsSolid Tumor, AdultNCT050995363D Medicines (Beijing) Co., Ltd.
已完成
1 期
Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male SubjectsHealthy Subjects, Overactive BladderNCT02938507Velicept Therapeutics, Inc.24